Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia

Soo-Young Yoon, Chin Yang Li, Ruben A. Mesa, Ayalew Tefferi

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

In a prospective study investigating the therapeutic role of anagrelide in myelofibrosis with myeloid metaplasia, 20 patients received anagrelide in daily oral doses of 0.5-3 mg. 17 patients were evaluable and received anagrelide for a median of 2 years (range 0.5-4 years). No patient had a clinically appreciable benefit. Bone marrow (BM) examinations at baseline and after 6 and 12 months of treatment were available for 17, 17 and 12 patients, respectively. In all evaluable cases, BM megakaryocyte number increased after 6 months of anagrelide treatment. Also, Ulex europaeus agglutinin-1 staining of megakaryocytes revealed a left-shifted maturation pattern in most patients with a platelet response to anagrelide. However, megakaryocyte staining intensity for transforming (TGF-β) and platelet-derived (PDGF) growth factors was not affected consistently by treatment. No patient had a ≥2 grade change in either BM fibrosis or osteosclerosis. These in-vivo data support our previous in-vitro observations that anagrelide interferes with megakaryocyte maturation rather than proliferation. Lack of a positive treatment effect is consistent with the finding that anagrelide did not significantly alter megakaryocyte expression of TGF-β and PDGF.

Original languageEnglish
Pages (from-to)682-688
Number of pages7
JournalBritish Journal of Haematology
Volume106
Issue number3
DOIs
Publication statusPublished - 1999 Sep 24

Fingerprint

Primary Myelofibrosis
Megakaryocytes
Bone Marrow
Therapeutics
Osteosclerosis
Staining and Labeling
Bone Marrow Examination
Platelet-Derived Growth Factor
anagrelide
Blood Platelets
Prospective Studies

Keywords

  • Megakaryocytes
  • Platelets

ASJC Scopus subject areas

  • Hematology

Cite this

Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia. / Yoon, Soo-Young; Li, Chin Yang; Mesa, Ruben A.; Tefferi, Ayalew.

In: British Journal of Haematology, Vol. 106, No. 3, 24.09.1999, p. 682-688.

Research output: Contribution to journalArticle

Yoon, Soo-Young ; Li, Chin Yang ; Mesa, Ruben A. ; Tefferi, Ayalew. / Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia. In: British Journal of Haematology. 1999 ; Vol. 106, No. 3. pp. 682-688.
@article{6450f87bc0ca4ef88175d5be9437e784,
title = "Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia",
abstract = "In a prospective study investigating the therapeutic role of anagrelide in myelofibrosis with myeloid metaplasia, 20 patients received anagrelide in daily oral doses of 0.5-3 mg. 17 patients were evaluable and received anagrelide for a median of 2 years (range 0.5-4 years). No patient had a clinically appreciable benefit. Bone marrow (BM) examinations at baseline and after 6 and 12 months of treatment were available for 17, 17 and 12 patients, respectively. In all evaluable cases, BM megakaryocyte number increased after 6 months of anagrelide treatment. Also, Ulex europaeus agglutinin-1 staining of megakaryocytes revealed a left-shifted maturation pattern in most patients with a platelet response to anagrelide. However, megakaryocyte staining intensity for transforming (TGF-β) and platelet-derived (PDGF) growth factors was not affected consistently by treatment. No patient had a ≥2 grade change in either BM fibrosis or osteosclerosis. These in-vivo data support our previous in-vitro observations that anagrelide interferes with megakaryocyte maturation rather than proliferation. Lack of a positive treatment effect is consistent with the finding that anagrelide did not significantly alter megakaryocyte expression of TGF-β and PDGF.",
keywords = "Megakaryocytes, Platelets",
author = "Soo-Young Yoon and Li, {Chin Yang} and Mesa, {Ruben A.} and Ayalew Tefferi",
year = "1999",
month = "9",
day = "24",
doi = "10.1046/j.1365-2141.1999.01598.x",
language = "English",
volume = "106",
pages = "682--688",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia

AU - Yoon, Soo-Young

AU - Li, Chin Yang

AU - Mesa, Ruben A.

AU - Tefferi, Ayalew

PY - 1999/9/24

Y1 - 1999/9/24

N2 - In a prospective study investigating the therapeutic role of anagrelide in myelofibrosis with myeloid metaplasia, 20 patients received anagrelide in daily oral doses of 0.5-3 mg. 17 patients were evaluable and received anagrelide for a median of 2 years (range 0.5-4 years). No patient had a clinically appreciable benefit. Bone marrow (BM) examinations at baseline and after 6 and 12 months of treatment were available for 17, 17 and 12 patients, respectively. In all evaluable cases, BM megakaryocyte number increased after 6 months of anagrelide treatment. Also, Ulex europaeus agglutinin-1 staining of megakaryocytes revealed a left-shifted maturation pattern in most patients with a platelet response to anagrelide. However, megakaryocyte staining intensity for transforming (TGF-β) and platelet-derived (PDGF) growth factors was not affected consistently by treatment. No patient had a ≥2 grade change in either BM fibrosis or osteosclerosis. These in-vivo data support our previous in-vitro observations that anagrelide interferes with megakaryocyte maturation rather than proliferation. Lack of a positive treatment effect is consistent with the finding that anagrelide did not significantly alter megakaryocyte expression of TGF-β and PDGF.

AB - In a prospective study investigating the therapeutic role of anagrelide in myelofibrosis with myeloid metaplasia, 20 patients received anagrelide in daily oral doses of 0.5-3 mg. 17 patients were evaluable and received anagrelide for a median of 2 years (range 0.5-4 years). No patient had a clinically appreciable benefit. Bone marrow (BM) examinations at baseline and after 6 and 12 months of treatment were available for 17, 17 and 12 patients, respectively. In all evaluable cases, BM megakaryocyte number increased after 6 months of anagrelide treatment. Also, Ulex europaeus agglutinin-1 staining of megakaryocytes revealed a left-shifted maturation pattern in most patients with a platelet response to anagrelide. However, megakaryocyte staining intensity for transforming (TGF-β) and platelet-derived (PDGF) growth factors was not affected consistently by treatment. No patient had a ≥2 grade change in either BM fibrosis or osteosclerosis. These in-vivo data support our previous in-vitro observations that anagrelide interferes with megakaryocyte maturation rather than proliferation. Lack of a positive treatment effect is consistent with the finding that anagrelide did not significantly alter megakaryocyte expression of TGF-β and PDGF.

KW - Megakaryocytes

KW - Platelets

UR - http://www.scopus.com/inward/record.url?scp=0032854508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032854508&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.1999.01598.x

DO - 10.1046/j.1365-2141.1999.01598.x

M3 - Article

VL - 106

SP - 682

EP - 688

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -